Gastroenterology ·
Composite biomarkers improve statistical efficiency in celiac disease trials
A methodology study applied continuous composite endpoints to data from two celiac disease studies, integrating histologic, serologic and immune biomarkers. The composites increased effect sizes in both datasets, while simulations suggested lower sample-size requirements when biomarkers had complementary responses and low-to-moderate correlation.
- Composite endpoints increased effect sizes in two celiac disease datasets.
- Simulated sample size fell from 90 to 45 under specified conditions.
- Efficiency gains depended on complementary biomarker responses.
- Prospective evaluation is needed before wider application.
Clinical trials in celiac disease often analyze histologic, immunologic and serologic biomarkers separately. Researchers developed a continuous composite endpoint (CCE) that standardizes complementary biomarkers onto a common scale, then evaluated it in secondary analyses of two previously published datasets: a 14-day gluten-challenge study assessing histologic deterioration and immune activation, and a 52-week study of newly diagnosed patients assessing recovery. Participant numbers were not reported in the supplied text.
In the gluten-challenge dataset, a composite of villous height-to-crypt depth ratio and intraepithelial lymphocytes had a Cohen’s d of 2.30, compared with 1.92 and 1.85 for the individual measures. In the recovery dataset, combining serology and tetramer measurements yielded a Cohen’s d of 2.47, versus 1.81 and 1.39, respectively. Simulations estimated that, with four complementary biomarkers each having an effect size of d=0.30 and inter-component correlation of 0.3, the sample size for 80% power fell from 90 for an individual biomarker to 45 for the CCE; type I error remained near 0.05.
The approach is a proof of concept, not evidence of improved patient outcomes or a basis for changing clinical care. Simulated efficiency gains diminished as biomarker correlation increased and were absent when response was mainly confined to one biomarker. Prospective evaluation is needed; one source dataset came from a Takeda-sponsored trial.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
BMC Medicine: A continuous composite endpoint methodology improves statistical efficiency: proof of concept in celiac disease ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.